Concepedia

Author

Basil Sharrack

University of SheffieldORCID

Also Known As

Azza Ishmail, B S Sharrack, B Sharrack, B. Sharrack, BASIL SHARRACK, Basil Sharrack, Clive Hawkins, David Rog, E. Idiman, Jeremy Hobart

328

Publications

12K

Citations

56

H-Index

205

Concepts

All Affiliations

University of SheffieldSheffield Teaching Hospitals NHS Foundation TrustRoyal Hallamshire HospitalInsigneoNorthumbria University
BS

About

Basil Sharrack is an author at University of Sheffield specializing in medicine, neurology, and multiple sclerosis.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Health Sciences

8

8

1.2K

2

Engineering

4

4

126

3

Language Studies

3

3

202

4

Education

2

2

277

5

Arts

1

1

58

Basil Sharrack

×

119

Publications

9.3K

Citations

50

H-Index

YearCitations

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree,

The Lancet

2018

896

A genetic study of Wilson’s disease in the United Kingdom

Alison J. Coffey, Miranda Durkie, Stephen Hague,

Brain

2013

353

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell,

The Lancet Neurology

2018

327

The effect of anti-α4 integrin antibody on brain lesion activity in MS

Niall Tubridy, P. O. Behan, Rudy Capildeo,

Neurology

1999

308

The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis

Basil Sharrack, Richard AC Hughes

Multiple Sclerosis Journal

1999

289

Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis

Richard K. Burt, Roumen Balabanov, Joachim Burman,

JAMA

2019

287

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

Giacomo P. Comi, Annalisa Pulizzi, Marco Rovaris,

The Lancet

2008

273

The psychometric properties of clinical rating scales used in multiple sclerosis

Basil Sharrack, Richard A. Hughes, Sara Soudain,

Brain

1999

254

MicroRNA‐155 negatively affects blood–brain barrier function during neuroinflammation

Miguel Alejandro Lopez‐Ramirez, Dongsheng Wu, Gareth Pryce,

The FASEB Journal

2014

252

Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE)

Basil Sharrack, Riccardo Saccardi, Tobias Alexander,

Bone Marrow Transplantation

2019

239

Page 1